


NYX-2925

Cat. No.:	HY-135741
CAS No.:	2012536-16-0
Molecular Formula:	C ₁₄ H ₂₃ N ₃ O ₄
Molecular Weight:	297.35
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (336.30 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.3630 mL	16.8152 mL	33.6304 mL
	5 mM	0.6726 mL	3.3630 mL	6.7261 mL
	10 mM	0.3363 mL	1.6815 mL	3.3630 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925 can be used for research of a variety of NMDA receptor-mediated central nervous system disorders^{[1][2]}.

IC₅₀ & Target

NMDA Receptor

REFERENCES

[1]. Morrison G, et al. The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC. *Neurobiol Pain*. 2019 Dec 4;7:100039.

[2]. Khan MA, et al. NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. *Int J Neuropsychopharmacol*. 2018 Mar 1;21(3):242-254.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA